Clinical Trial Update: Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study of GSK2336805 in subjects with hepatic impairment and matched healthy controls has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK2336805

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED